The Vent-Os System achieved post-procedural patency in 95 percent of the sinus ostia treated in a multi-center study and submitted as part of the Company’s FDA application; five percent of the treated ostia could not be visualized. In the study, the Vent-Os device was inserted into the maxillary sinus opening at the beginning of the procedure and removed after 60 minutes. No adverse events occurred during insertion or removal of the device. Three-month follow-up was completed in 33 patients (55 ostia), with 93 percent of the treated ostia remaining patent and seven percent that could not be visualized. No ostia were reported to be occluded. At 6 months, 30 patients were available for follow-up and 45/49 (92%) of treated ostia were visibly patent with 4/49 (8%) “indeterminate”; no maxillary ostia were clinically non-functional. At 12 months, 27 patients with 45 treated ostia were available for evaluation, with 93 percent of ostia (42) visibly patent and seven percent (3) unable to be visualized. All ostia were clinically functional¹

Fifteen percent of patients in the study were treated in an office setting after pre-procedural injection of anesthesia; no additional anesthesia or medication was required for these patients for the duration of the procedure. This is in contrast to balloon dilation devices, which often require administration of anxiolytics, analgesics and/or additional local injections of anesthetics during the procedure to increase patient tolerability. The remaining patients were treated in the operating room adjunctive to functional endoscopic sinus surgery (FESS).

The Vent-Os® Sinus Dilation System is an instrument intended to provide a means to access the sinus space and to dilate the maxillary sinus ostia and associated spaces in adults for diagnostic and therapeutic procedures.